The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.

MLA

Eiermann, W., et al. “The 21-Gene Recurrence Score Assay Impacts Adjuvant Therapy Recommendations for ER-Positive, Node-Negative and Node-Positive Early Breast Cancer Resulting in a Risk-Adapted Change in Chemotherapy Use.” Annals of Oncology, vol. 24, no. 3, Mar. 2013, pp. 618–24. EBSCOhost, https://doi.org/10.1093/annonc/mds512.

APA

Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., & Blohmer, J. (2013). The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Annals of Oncology, 24(3), 618–624. https://doi.org/10.1093/annonc/mds512

Chicago

Eiermann, W., M. Rezai, S. Kümmel, T. Kühn, M. Warm, K. Friedrichs, A. Schneeweiss, et al. 2013. “The 21-Gene Recurrence Score Assay Impacts Adjuvant Therapy Recommendations for ER-Positive, Node-Negative and Node-Positive Early Breast Cancer Resulting in a Risk-Adapted Change in Chemotherapy Use.” Annals of Oncology 24 (3): 618–24. doi:10.1093/annonc/mds512.